Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.42% -0.06% 158.90M 16022.30
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.00% 36.10% 70.72M Upgrade

Basic Info

Investment Strategy
The investment seeks to provide investment results that closely correspond, before expenses, to the performance of the Nasdaq Healthcare Innovators Index (the "index"). Under normal circumstances, the fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies that compose the index at the time of purchase. The index uses a quantitative model designed to identify equity securities in the Nasdaq US Benchmark Index that are small and medium capitalization U.S. healthcare companies.
General
Security Type Exchange-Traded Fund
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Principal Funds
Prospectus Benchmark Index
NASDAQ US Health Care Innovators TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Jeffrey Schwarte 4.70 yrs
Aaron Siebel 1.16 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 20
70.72M
-4.429B Category Low
8.106B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of April 30, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of May 07, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
--
--
36.93%
-12.24%
39.64%
52.91%
-6.75%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
11.38%
--
27.86%
-27.83%
45.63%
-11.71%
50.30%
21.17%
-9.99%
14.75%
1.51%
-12.90%
50.15%
-1.23%
34.45%
67.26%
-6.35%
44.98%
13.58%
-15.45%
43.77%
-15.27%
32.56%
48.33%
-9.24%
11.13%
20.27%
1.67%
34.87%
9.15%
20.17%
31.47%
9.63%
As of May 07, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-7-21) 0.00%
30-Day SEC Yield (4-30-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of April 30, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of April 30, 2021

Asset Allocation

As of April 30, 2021.
Type % Net % Long % Short
Cash 0.20% Upgrade Upgrade
Stock 99.80% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Seagen Inc Ordinary Shares 3.04% 139.49 2.51%
Exact Sciences Corp 2.94% 104.50 -3.25%
Teladoc Health Inc 2.78% 151.04 -0.57%
Insulet Corp 2.60% 234.19 -7.49%
10x Genomics Inc Ordinary Shares - Class A 2.27% 146.36 1.32%
Alnylam Pharmaceuticals Inc 2.19% 131.30 -0.61%
Guardant Health Inc 2.13% 135.39 0.57%
Novavax Inc 2.01% 176.00 2.02%
Elanco Animal Health Inc 2.00% 32.88 5.89%
Biomarin Pharmaceutical Inc 1.89% 77.77 -1.07%

News

Basic Info

Investment Strategy
The investment seeks to provide investment results that closely correspond, before expenses, to the performance of the Nasdaq Healthcare Innovators Index (the "index"). Under normal circumstances, the fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies that compose the index at the time of purchase. The index uses a quantitative model designed to identify equity securities in the Nasdaq US Benchmark Index that are small and medium capitalization U.S. healthcare companies.
General
Security Type Exchange-Traded Fund
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Principal Funds
Prospectus Benchmark Index
NASDAQ US Health Care Innovators TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Jeffrey Schwarte 4.70 yrs
Aaron Siebel 1.16 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (5-7-21) 0.00%
30-Day SEC Yield (4-30-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of April 30, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of April 30, 2021

Fund Details

Key Dates
Inception Date 8/19/2016
Last Annual Report Date 6/30/2020
Last Prospectus Date 11/1/2020
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

News